Results 31 to 40 of about 4,310 (188)

Medication-related osteonecrosis of the jaw

Revista Brasileira de Odontologia, 2018
.
Heliton Spindola Antunes, Rogerio Jardim Caldas, Fabiana Caramori Noal Granzotto, Geisa Badauy Lauria Da Silva, Walmir Mello, Paulo Sérgio Da Silva Santos   +5 more
openaire   +3 more sources

Medication-related osteonecrosis of the jaw: a dentist's nightmare [PDF]

BMJ Case Reports, 2016
Medication-related osteonecrosis of the jaw (MRONJ) is a complication in patients who are on anti-bone resorptive drugs. These drugs are prescribed for patients with multiple myeloma, osteoporosis, metastatic carcinoma and Paget's disease. Common anti-bone resorptive drugs such as bisphosphonate and monoclonal antibodies such as denosumab are ...
Arvind, Muthukrishnan, Laliytha, Bijai Kumar, Gomathi, Ramalingam   +2 more
openaire   +2 more sources

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Case Reports in Dentistry, 2016
Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in
Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini   +8 more
doaj   +1 more source

Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw

Pharmaceuticals, 2022
Medication-related osteonecrosis of the jaw (MRONJ) is an intractable disease that is typically observed in patients with osteoporosis or tumors that have been treated with either bisphosphonate (BP) or antiangiogenic medicine.
Ken Matsunaka, Mikio Imai, Koma Sanda, Noriyuki Yasunami, Akihiro Furuhashi, Ikiru Atsuta, Hiroko Wada, Yasunori Ayukawa   +7 more
doaj   +1 more source

Management of severe bone loss in patients at risk of medication‐related osteonecrosis of the jaw with microsurgery and guided bone regeneration: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira, José Maurício Paradella de Camargo, Lara Maria Alencar Ramos Innocentini, Ana Carolina Fragoso Motta   +3 more
wiley   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review

Journal of Research in Medical Sciences, 2021
Medication related osteonecrosis of the jaw (MRONJ) is a severe condition affecting the jaws of patients exposed to specific drugs, and is primarily described in patients receiving bisphosphonate (BP) therapy.
Roberto Sacco, Julian Woolley, Julian Yates, Monica Diuana Calasans-Maia, Oladapo Akintola, Vinod Patel   +5 more
doaj   +1 more source

Estradiol replacement attenuates alendronate‐associated adverse effects on alveolar bone repair in ovariectomized rats

Journal of Periodontology, EarlyView.
Abstract Background Sodium alendronate (ALN) is widely used to treat postmenopausal osteoporosis, but both estrogen deficiency and antiresorptive therapy may impair alveolar bone repair after tooth extraction. A clinically relevant but insufficiently explored scenario involves estrogen‐deficient individuals receiving hormone replacement therapy (HRT ...
Pedro H. C. Isaias, Paulo G. B. Silva, Isabelly V. do Nascimento, Raul A. D. A. da Silva, Thayla M. do C. Sousa, Ana J. A. de de Vasconcelos, José V. M. Lemos, Fabrício B. Sousa, Ana P. N. N. Alves, Mário R. L. Mota   +9 more
wiley   +1 more source